Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-309 tarlatamab dosing regimens in relapsed small cell lung cancer
2024-516051-40-00Phase 2Authorised
- Sponsor
- Amgen
- Start
- Jun 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of tarlatamab in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoints: Confirmed objective response, Complete response and 1 more. Planned start Jun 2025; status: authorised.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-516051-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516051-40-00.